Drug Trial Radar · NCT00221000
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Oct 19, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
86
Actual
Start
Aug 2003
Primary completion
Oct 2006
Study completion Nov 2006
Sponsor
- Lead sponsor
- MallinckrodtIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disorder that can cause substantial pain and joint tenderness, significant joint damage, and serious disability. The treatment goals are minimization of the signs and symptoms of the disease, and the reduction of irreversible joint damage. As the understanding of the pathophysiological mechanisms underlying RA is elucidated, the opportunity to target specific inflammatory processes with new therapies has improved. Rheumatoid arthritis is a T cell-mediated autoimmune disease and there are various therapies, including newer experimental therapies, which target either the activation of T cells or the neutralization of their effector mechanisms. These newer therapies have shown benefit in human and animal models of RA. Extracorporeal photoimmune therapy (ECP) has been shown to be safe and effective in the palliative treatment of the skin manifestations of cutaneous T cell lymphoma. Experimental studies have also demonstrated activity of ECP treatment in several T cell mediated diseases including graft versus-host disease, rejection after organ transplantation, and selected autoimmune diseases. This study will evaluate a cell-based therapy (ECP) in patients who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs) and biological agents to determine if ECP treatment can reduce the signs and symptoms of RA in this refractory patient population.
Conditions
- Rheumatoid Arthritis
Interventions
MethoxsalenDrug
Extracorporeal PhotopheresisProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR 20Time frame: week 24 and week 28
Locations
32 sites in 11 countries. Site status is shown where the registry gives one.
Carroll County Arthritis and Osteoporosis Center
Westminister, Maryland
Clinical Pharmacology Study Group
Worchester, Massachusetts
Morristown Memorial Hospital
Morristown, New Jersey
AAIR Research Center
Rochester, New York
Carolina Arthritis Associates
Wilmington, North Carolina
Rheumatic Disease Associates
Willow Grove, Pennsylvania
Rheumatology Associates
Providence, Rhode Island
UT Southwestern Medical Center
Dallas, Texas
Arthritis and Osteoporosis Center of South Texas
San Antonio, Texas
Benaroya Research Institute at Virginia Mason
Seattle, Washington
Royal Brisbane Hospital
Herston, Australia
General Hospital of Vienna
Vienna, Austria
Hospital Brugmann
Brussels, Belgium
Limburgs Universitair Centrum
Diepenbeek, Belgium
Rebecca MacDonald Centre for Arthritis
Toronto, Ontario, Canada
CHRU de Lille
Lille, France
Hopital Edouard Herriot
Lyon, France
Franz von Prummer Klinik
Bad Brückenau, Germany
University of Charite Clinic for Rheumatology and Immunology
Berlin, Germany
Klinikum der Universitat zu Koln
Cologne, Germany
Medizinische Klinik III
Erlangen, Germany
Abt. Rheumatologie und Klinische Immunologie
Hamburg, Germany
Westfalische wilhelms-universitat Munster
Münster, Germany
Medizinische Klinik des Evangelischen Kranken
Oldenburg, Germany
Universita degli Studi di Firenze
Florence, Italy
Universita de Genova - Ospedale S. Martino
Genova, Italy
University of Siena-Italy
Siena, Italy
OPD- Hospital Civil "Dr. Jaun I. Menchaca"
Guadalajara, Jalisco, Mexico
Reumatologicka ambulancia, Polinika
Bratislava, Slovakia
South African National Blood Service
Bloemfontein, South Africa
Christian Barnard Mermorial Hospital
Cape Town, South Africa
D6 Rheumatology Clinic and E5 Hematology Unit
Cape Town, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.